On the 24th of February Ivars Kalvinsh, Chairman of the Board of Institute of Organic Synthesis (IOS) has become a shareholder in the international holding-company “Rigvir”, being a leading participant on the pharmacy market in the field of virotherapy.
IOS is well known on international level. Since 1957 institute performs research in organic chemistry, molecular biology and bioorganic chemistry. Within several decades IOS has developed 20 internationally recognized drugs, including such as Mildronate and Leokadin. IOS also participated in invention of registered in 2014 by the USA FDA standards medicine Belinostat (Beleodaq), that is regarded the best of its kind for the treatment of hematological malignancies. Together with business partners IOS has been filed more than 270 patents in the last 5 years.
Professor I.Kalvinsh "... I am very satisfied with this deal and I hope that I will be able to help in developing this unique medicine even more successfully. Rigvir certainly can be recognized as a drug with the so far unprecedented principle of action and the perspectives of such treatment are impossible to overestimate. I will do everything that depends on me in order to make the development of Rigvir and virotherapy a success story not only for my country - Latvia, but also for many cancer patients around the world, who have deserved humane and effective treatment long ago...”
Chairman of Rigvir holding J.Auzinsh "... the fact that honourable and worldwide known scientist and pharmacy expert Ivars Kalvinsh became a shareholder of Rigvir holding is a logical step in our relationships, and we are very pleased with such addition to our team. This deal is a good signal to our existing and potential partners and, also it should become a strong impulse to the entire pharmaceutical world...”
Rigvir Holding was founded in 2013 and combines a number of companies, that are manufacturing and promoting in pharmaceutical markets a unique medicine Rigvir, as well as developing medical branch of cancer virotherapy in the whole world.
As it is known, Rigvir has been invented and developed in EU member-state – Latvia, and registered as the first in the world anti-cancer medicine, containing live virus, which is to date the only drug that represents a new perspective and oncology branch – cancer virotherapy. Rigvir is being compensated from the state and the manufacturer for Latvian patients and currently virotherapy with Rigvir has been used for treating patients from already more than 40 countries.
Contact information: +37125605777, rigvir@rigvir.com
More information: www.rigvir.com
Help employers find you! Check out all the jobs and post your resume.
IOS is well known on international level. Since 1957 institute performs research in organic chemistry, molecular biology and bioorganic chemistry. Within several decades IOS has developed 20 internationally recognized drugs, including such as Mildronate and Leokadin. IOS also participated in invention of registered in 2014 by the USA FDA standards medicine Belinostat (Beleodaq), that is regarded the best of its kind for the treatment of hematological malignancies. Together with business partners IOS has been filed more than 270 patents in the last 5 years.
Professor I.Kalvinsh "... I am very satisfied with this deal and I hope that I will be able to help in developing this unique medicine even more successfully. Rigvir certainly can be recognized as a drug with the so far unprecedented principle of action and the perspectives of such treatment are impossible to overestimate. I will do everything that depends on me in order to make the development of Rigvir and virotherapy a success story not only for my country - Latvia, but also for many cancer patients around the world, who have deserved humane and effective treatment long ago...”
Chairman of Rigvir holding J.Auzinsh "... the fact that honourable and worldwide known scientist and pharmacy expert Ivars Kalvinsh became a shareholder of Rigvir holding is a logical step in our relationships, and we are very pleased with such addition to our team. This deal is a good signal to our existing and potential partners and, also it should become a strong impulse to the entire pharmaceutical world...”
Rigvir Holding was founded in 2013 and combines a number of companies, that are manufacturing and promoting in pharmaceutical markets a unique medicine Rigvir, as well as developing medical branch of cancer virotherapy in the whole world.
As it is known, Rigvir has been invented and developed in EU member-state – Latvia, and registered as the first in the world anti-cancer medicine, containing live virus, which is to date the only drug that represents a new perspective and oncology branch – cancer virotherapy. Rigvir is being compensated from the state and the manufacturer for Latvian patients and currently virotherapy with Rigvir has been used for treating patients from already more than 40 countries.
Contact information: +37125605777, rigvir@rigvir.com
More information: www.rigvir.com
Help employers find you! Check out all the jobs and post your resume.
